Basic Fibroblast Growth Factor Attenuates Injury in Myocardial Infarction by Enhancing Hypoxia-Inducible Factor-1 Alpha Accumulation

Overview

Journal Front Pharmacol

Date 2020 Aug 28

PMID 32848793

Citations 11

Authors

Zhiheng Rao

Danping Shen

Jiahui Chen

Lushen Jin

Xueping Wu

Ming Chen

Lei Li

Maoping Chu

Jiafeng Lin

Affiliations

Soon will be listed here.

Abstract

Background: The combination of antiapoptotic and angiogenic actions may represent a pharmacotherapeutic strategy for the treatment of myocardial infarction. Fibroblast growth factor (FGF) is expressed in various cell types including endothelial and muscle cells and promotes their survival, migration, and proliferation.

Methods And Results: Myocardial microvascular endothelial cells were divided into four treatment groups, the sham, hypoxia, basic FGF (bFGF), and bFGF plus 2-methoxyestradiol groups, and subjected to apoptotic analysis and Matrigel assays. An model of myocardial infarction was established by ligaturing the left coronary artery of mice in the four treatment groups. Cardiac performance, myocardial injury, endothelial cell angiogenesis, and myocardial apoptosis were assessed. bFGF administration after myocardial infarction improved cardiac function and cell viability, attenuated myocardial injury and apoptosis, and enhanced angiogenesis. Western blotting of HIF-1α, p-AKT, VEGF, p53, BAX, and Bcl-2 showed that bFGF increased HIF-1α, p-AKT, VEGF, and Bcl-2 and decreased BAX protein levels.

Conclusion: The results of the present study indicated that bFGF attenuates myocardial injury by inhibiting apoptosis and promoting angiogenesis a novel HIF-1α-mediated mechanism and a potential utility of bFGF in protecting against myocardial infarction.

Citing Articles

Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy.

Gao S, Li D, Wang B, Zhang H, Chen L Front Cardiovasc Med. 2025; 12:1540066.

PMID: 40046966 PMC: 11880279. DOI: 10.3389/fcvm.2025.1540066.

Enhanced human adipose-derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction.

Li K, Luo R, Yu X, Dong W, Hao G, Hu D Clin Transl Med. 2025; 15(3):e70250.

PMID: 40008489 PMC: 11862888. DOI: 10.1002/ctm2.70250.

Bioinspired Collagen Scaffold Loaded with bFGF-Overexpressing Human Mesenchymal Stromal Cells Accelerating Diabetic Skin Wound Healing via HIF-1 Signal Pathway Regulated Neovascularization.

Huang F, Gao T, Feng Y, Xie Y, Tai C, Huang Y ACS Appl Mater Interfaces. 2024; 16(35):45989-46004.

PMID: 39165237 PMC: 11378764. DOI: 10.1021/acsami.4c08174.

A literature review of bioactive substances for the treatment of periodontitis: , and clinical studies.

Kim T, Heo S, Chandika P, Kim Y, Kim H, Kang H Heliyon. 2024; 10(2):e24216.

PMID: 38293511 PMC: 10826675. DOI: 10.1016/j.heliyon.2024.e24216.

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).

PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.

References

Lin Y, Li L, Liu J, Zhao X, Ye J, Reinach P . SIRT1 Deletion Impairs Retinal Endothelial Cell Migration Through Downregulation of VEGF-A/VEGFR-2 and MMP14. Invest Ophthalmol Vis Sci. 2018; 59(13):5431-5440. DOI: 10.1167/iovs.17-23558. View

Ornitz D, Itoh N . The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66. PMC: 4393358. DOI: 10.1002/wdev.176. View

Szebenyi G, Fallon J . Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol. 1998; 185:45-106. DOI: 10.1016/s0074-7696(08)60149-7. View

Post M, Laham R, Sellke F, Simons M . Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res. 2001; 49(3):522-31. DOI: 10.1016/s0008-6363(00)00216-9. View

Gaziano T . Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005; 112(23):3547-53. DOI: 10.1161/CIRCULATIONAHA.105.591792. View

Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2014; 131(4):e29-322. DOI: 10.1161/CIR.0000000000000152. View

Masoud G, Li W . HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015; 5(5):378-89. PMC: 4629436. DOI: 10.1016/j.apsb.2015.05.007. View

Schultz J, Witt S, Nieman M, Reiser P, Engle S, Zhou M . Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999; 104(6):709-19. PMC: 408439. DOI: 10.1172/JCI7315. View

Fihn S, Gardin J, Abrams J, Berra K, Blankenship J, Dallas A . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,.... J Am Coll Cardiol. 2012; 60(24):e44-e164. DOI: 10.1016/j.jacc.2012.07.013. View

10.

Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A . Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem. 2002; 277(45):42919-25. DOI: 10.1074/jbc.M206141200. View

11.

Detillieux K, Sheikh F, Kardami E, Cattini P . Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res. 2002; 57(1):8-19. DOI: 10.1016/s0008-6363(02)00708-3. View

12.

Wang Y, Tang Y, Yang M, Huang X . Dexmedetomidine alleviates cerebral ischemia-reperfusion injury in rats via inhibition of hypoxia-inducible factor-1α. J Cell Biochem. 2018; 120(5):7834-7844. DOI: 10.1002/jcb.28058. View

13.

Nabel E, Braunwald E . A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012; 366(1):54-63. DOI: 10.1056/NEJMra1112570. View

14.

Bagai A, Dangas G, Stone G, Granger C . Reperfusion strategies in acute coronary syndromes. Circ Res. 2014; 114(12):1918-28. DOI: 10.1161/CIRCRESAHA.114.302744. View

15.

Semenza G . HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001; 13(2):167-71. DOI: 10.1016/s0955-0674(00)00194-0. View

16.

Kimura W, Xiao F, Canseco D, Muralidhar S, Thet S, Zhang H . Hypoxia fate mapping identifies cycling cardiomyocytes in the adult heart. Nature. 2015; 523(7559):226-30. DOI: 10.1038/nature14582. View

17.

Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y . p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446(7134):444-8. DOI: 10.1038/nature05602. View

18.

Sheikh F, Sontag D, Fandrich R, Kardami E, Cattini P . Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol. 2001; 280(3):H1039-50. DOI: 10.1152/ajpheart.2001.280.3.H1039. View

19.

Palmen M, Daemen M, De Windt L, Willems J, Dassen W, Heeneman S . Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll Cardiol. 2004; 44(5):1113-23. DOI: 10.1016/j.jacc.2004.05.067. View

20.

Fordyce C, Gersh B, Stone G, Granger C . Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol Sci. 2015; 36(9):605-16. DOI: 10.1016/j.tips.2015.06.004. View